Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 12.01.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 23.12.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | . ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Offic |
| 02.07.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | tory Note and in Item 1.01, Item 2.01, Item 3.02, Item 5.02 and Item 5.03 to this Current Report is incorporated by refe |
| 18.11.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | rporated by reference into this Item 3.03. Item 5.02. Departure of Directors or Certain Officers; Appointment of Certa |
| 18.03.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
Stammdaten
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
Unternehmen & Branche
| Name | Pelthos Therapeutics Inc. |
|---|---|
| Ticker | PTHS |
| CIK | 0001919246 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 16,1 Mio. USD |
| Beta | 3,99 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 16,795,000 | -43,319,000 | -23.04 | 130,397,000 | 38,881,000 |
| 2025-09-30 | 10-Q | 7,406,000 | -16,238,000 | -5.30 | 126,433,000 | 58,253,000 |
| 2025-06-30 | 10-Q | -3,449,000 | -5.38 | 822,850 | -6,494,000 | |
| 2025-03-31 | 10-Q | -1,968,000 | -0.32 | 911,179 | -4,196,000 | |
| 2024-12-31 | 10-K | 0 | -7,955,000 | -14.27 | 1,369,000 | -2,714,000 |
| 2024-09-30 | 10-Q | -1,695,000 | -2.93 | 2,139,888 | -1,428,000 | |
| 2024-06-30 | 10-Q | -1,772,000 | -3.07 | 2,603,600 | -184,000 | |
| 2024-03-31 | 10-Q | -2,562,000 | -0.55 | 4,031,559 | 1,130,000 | |
| 2023-12-31 | 10-K | -7,380,793 | -5.78 | 96,391 | -6,445,000 | |
| 2023-09-30 | 10-Q | -1,421,732 | -5,904,588 | |||
| 2023-06-30 | 10-Q | -953,347 | -4,900,886 | |||
| 2023-03-31 | 10-Q | -966,561 | -4,440,877 | |||
| 2022-12-31 | 10-K | -2,458,589 | 55,074 | -3,706,537 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-02 | Friedberg Ezra M | Director | Open Market Sale | -293 | 20.51 | -6,010.05 | -18,7% | |
| 2026-04-02 | Greenleaf Peter | Director | Open Market Sale | -420 | 20.52 | -8,616.34 | -26,8% | |
| 2026-04-02 | Malamut Richard | Director | Open Market Sale | -280 | 21.36 | -5,981.14 | -18,6% | |
| 2026-04-02 | Malamut Richard | Director | Open Market Sale | -310 | 20.51 | -6,358.91 | -19,8% | |
| 2026-04-02 | Friedberg Ezra M | Director | Open Market Sale | -265 | 21.36 | -5,660.72 | -17,6% | |
| 2026-04-02 | Greenleaf Peter | Director | Open Market Sale | -377 | 21.36 | -8,053.25 | -25,1% | |
| 2025-11-25 | Friedberg Ezra M | Director | Open Market Sale | -2,000 | 28.01 | -56,010.00 | -174,5% | |
| 2025-11-25 | Friedberg Ezra M | Director | Open Market Sale | -2,000 | 28.14 | -56,270.00 | -175,3% | |
| 2025-11-25 | Friedberg Ezra M | Director | Open Market Sale | -5,999 | 28.00 | -167,972.00 | -523,3% | |
| 2025-11-25 | Friedberg Ezra M | Director | Open Market Sale | -1 | 28.50 | -28.50 | -0,1% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.